Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
第一作者:
Richard S,Finn
第一单位:
Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA. RFinn@mednet.ucla.edu.
作者:
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);人类(Humans);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);中性粒细胞减少(Neutropenia);腈类(Nitriles);哌嗪类(Piperazines);吡啶类(Pyridines);受体, 雌激素(Receptors, Estrogen);再治疗(Retreatment);存活率分析(Survival Analysis);治疗结果(Treatment Outcome);三唑类(Triazoles)
DOI
10.1186/s13058-016-0721-5
PMID
27349747
发布时间
2022-03-21
- 浏览102
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



